ANI Pharmaceuticals market cap ANIP
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $1.6B
- Highest close in our data
- $2.1B
- Sep 2025
ANI Pharmaceuticals is worth $1.6B at the close on Nov 2, 2026, at $70.67 a share.
That is down 20% over the last year and up 155% over five years.
Its highest close in our data was $2.1B in Sep 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.6B | $1.6B | $2B | −12% |
| 2025 | $1.9B | $1.2B | $2.1B | +62% |
| 2024 | $1.1B | $1.1B | $1.5B | +2% |
| 2023 | $1.1B | $658.3M | $1.3B | +60% |
| 2022 | $702.6M | $420.5M | $727.6M | +20% |
| 2021 | $587.6M | $350.2M | $649.1M | +64% |
| 2020 | $358.9M | $292.8M | $793.9M | −52% |
| 2019 | $741.5M | $578.9M | $1B | +43% |
| 2018 | $520.2M | $488.2M | $842.6M | −31% |
| 2017 | $751.1M | $510.9M | $868.9M | +7% |
| 2016 | $702.7M | $333.6M | $801.9M | +35% |
| 2015 | $518.9M | $474.2M | $811.5M | −16% |
| 2014 | $617.9M | $178.7M | $623.7M | +227% |
| 2013 | $188.8M | $23.3M | $188.8M | +517% |
| 2012 | $30.6M | $27.4M | $93.5M | −44% |
| 2011 | $55M | $49.5M | $302.5M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest ANI Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| ANIPANI Pharmaceuticals | $1.6B |
| PAHCPhibro Animal Health | $1.6B |
| PCRXPacira BioSciences | $1.5B |
| ANABAnaptysbio | $1.4B |
| OMEROmeros | $1.3B |
| HRMYHarmony Biosciences | $2.2B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| PBHPrestige Consumer Healthcare | $2.4B |
| NRIXNurix Therapeutics | $2.8B |
| ABUSArbutus Biopharma | $791.4M |
| COLLCollegium Pharmaceutical | $770.9M |
| Peer median | $1.4B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on ANI Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.